Lifecore Biomedical Valuation Multiples

Lifecore Biomedical Overview

About Lifecore Biomedical

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.

Founded

1986

HQ

Employees

406

Website

lifecore.com

Sectors

Contract Research & ManufacturingBioTech

Financials (LTM)

Revenue: $96M

EBITDA: $17M

EV

$388M

Valuation Multiples

Multiples.vc

Start free trial

Lifecore Biomedical Financials

Lifecore Biomedical reported last 12-month revenue of $96M and EBITDA of $17M.

In the same LTM period, Lifecore Biomedical generated $23M in gross profit, $17M in EBITDA, and had net loss of ($25M).

Lifecore Biomedical P&L

In the most recent fiscal year, Lifecore Biomedical reported revenue of $129M and EBITDA of $13M.

Lifecore Biomedical expects next 12-month revenue of XXX and NTM EBITDA of XXX

Lifecore Biomedical Stock Performance

Lifecore Biomedical has current market cap of $271M, and enterprise value of $388M.

Lifecore Biomedical's stock price is $7.23.

Lifecore Biomedical Valuation Multiples

Lifecore Biomedical trades at 4.0x EV/Revenue multiple, and 23.5x EV/EBITDA.

Lifecore Biomedical Financial Valuation Multiples

As of April 8, 2026, Lifecore Biomedical has market cap of $271M and EV of $388M.

Equity research analysts estimate Lifecore Biomedical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Lifecore Biomedical has a P/E ratio of (10.9x).

Lifecore Biomedical Margins & Growth Rates

Lifecore Biomedical's revenue in the last 12 month grew by 30%.

Lifecore Biomedical's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Lifecore Biomedical's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Lifecore Biomedical's rule of X is 25% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Lifecore Biomedical Public Comps

See public comps and valuation multiples for other Contract Research & Manufacturing comps.

Lifecore Biomedical M&A Activity

Lifecore Biomedical acquired XXX companies to date.

Last acquisition by Lifecore Biomedical was on XXXXXXXX, XXXXX. Lifecore Biomedical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Lifecore Biomedical Investment Activity

Lifecore Biomedical invested in XXX companies to date.

Lifecore Biomedical made its latest investment on XXXXXXXX, XXXXX. Lifecore Biomedical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).